Terms & Conditions
Please read our conditions of use carefully as by using the website you will be assumed to have agreed to be bound by them.
Search results
Please read our conditions of use carefully as by using the website you will be assumed to have agreed to be bound by them.
Thank you to all those who completed our recent Sight Loss Survey – almost 700 of you took the time to share your experiences.
UK researchers have discovered that passing a weak electrical current between electrodes on a person’s scalp may lead to a reduction in frequency of the visual hallucinations experienced by some people living with sight loss.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
The Dr Jessie Mole lecture was inaugurated on 10 December 2001, in recognition of Jessie's outstanding contribution to BRPS, then RP Fighting Blindness and now Retina UK.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Octant, a clinical stage drug discovery company, has recently announced the dosing of the first healthy volunteer in their Phase 1a clinical trial of OCT-980 for Rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP).
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
The following projects were being funded by Retina UK and have recently come to an end.